» Articles » PMID: 9772903

Interphase Cytogenetics of Esophageal Adenocarcinoma and Precursor Lesions

Overview
Date 1998 Oct 17
PMID 9772903
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Limited information is currently available on chromosomal abnormalities in esophageal adenocarcinoma and associated premalignant lesions. In this study, numeric changes affecting chromosomes 4, 6, 7, 8, 9, 10, 11, 12, 17, 18, X, and Y were analyzed by using fluorescence in situ hybridization (FISH) with chromosome-specific centromere DNA probes in 12 esophageal adenocarcinomas. In addition, TP53 overexpression, measured by immunohistochemistry, and amplification of HER-2/neu and C-MYC, detected by FISH, were analyzed within the same tumors. The most common numeric abnormalities detected were gains of chromosomes 12 (8 cases), 6 (7 cases), 7 (7 cases), and 11 (6 cases). The total number of abnormal chromosomes varied from 0 to 10, with an average of 4.6 per case. Overexpression of TP53 was present in 9 of 12 cases. No correlation was noted between the degree of aneusomy and TP53 overexpression. In contrast, HER-2/neu amplification was present in two cases, both with large numbers of aneusomic chromosomes. Amplification of C-MYC was detected in only one case that had a moderate number of numeric abnormalities. In a subset of cases in which premalignant lesions were examined, aneusomy was found to be an early change, frequently present in both Barrett's esophagus and dysplastic regions. In contrast, gene amplification and TP53 overexpression were restricted to more advanced areas of dysplasia and malignancy. Screening larger cohorts of patients with Barrett's esophagus or dysplasia for numeric abnormalities of chromosomes 6, 7, 11, and 12 may determine whether any of these abnormalities are predictive markers of progression to malignancy.

Citing Articles

Patterns of Aneuploidy and Signaling Consequences in Cancer.

Zhakula-Kostadinova N, Taylor A Cancer Res. 2024; 84(16):2575-2587.

PMID: 38924459 PMC: 11325152. DOI: 10.1158/0008-5472.CAN-24-0169.


The Mechanisms for the Association of Cancer and Esophageal Dysmotility Disorders.

Tustumi F, Sousa J, Dornelas N, Rosa G, Steinman M, Bianchi E Med Sci (Basel). 2021; 9(2).

PMID: 34064058 PMC: 8163009. DOI: 10.3390/medsci9020032.


Y Chromosome Loss is a Frequent Event in Barrett's Adenocarcinoma and Associated with Poor Outcome.

Loeser H, Wolwer C, Alakus H, Chon S, Zander T, Buettner R Cancers (Basel). 2020; 12(7).

PMID: 32629877 PMC: 7408596. DOI: 10.3390/cancers12071743.


From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma.

Gokulan R, Garcia-Buitrago M, Zaika A Biochim Biophys Acta Rev Cancer. 2019; 1872(1):37-48.

PMID: 31152823 PMC: 6692203. DOI: 10.1016/j.bbcan.2019.05.003.


Genetic Insights in Barrett's Esophagus and Esophageal Adenocarcinoma.

Reid B, Paulson T, Li X Gastroenterology. 2015; 149(5):1142-1152.e3.

PMID: 26208895 PMC: 4589483. DOI: 10.1053/j.gastro.2015.07.010.